Tag:

Johnson & Johnson

Latest Headlines

Latest Headlines

J&J shoring up for latest courtroom battle over all-metal hip implant

Long beleaguered by claims related to defective all-metal hip implants, Johnson & Johnson is shoring up for its latest courtroom battle as the company faces the first trial for one of its artificial hip devices.

J&J looks to sell off Cordis for as much as $2B

Johnson & Johnson is reportedly seeking a buyer for its Cordis unit, which is focused on vascular medical devices. This would be the second major divestiture for the conglomerate this year, it sold Ortho-Clinical Diagnostics to private equity firm The Carlyle Group in June for $4.2 billion.

J&J's DePuy Synthes unit slapped with FDA Class I recall for jaw-stabilizing device

Johnson & Johnson's DePuy Synthes unit is facing regulators' ire as the FDA slapped the company's recall of its jaw-stabilizing device with a Class I label, its most serious designation.

J&J pours another $20M into ViaCyte and sizes up its diabetes treatment

Johnson & Johnson has deepened its ties to regenerative medicine outfit ViaCyte, handing the biotech $20 million in exchange for a future stake in the company and the right to acquire its in-development diabetes medication.

J&J, AstraZeneca and Sanofi join Illumina to create a pan-cancer test

Pharma giants AstraZeneca, Johnson & Johnson and Sanofi have teamed up with gene sequencing pioneer Illumina to create a single test that screen patients for a wealth of cancer-related gene variants, allowing drugmakers to identify the ideal recipients of their oncology drugs.

NICE Zytiga snub is 'plainly illogical,' critic says

U.K.'s National Institute for Health and Care Excellence has delivered a blow to Johnson & Johnson's Zytiga in final draft guidance recommending against the prostate cancer pill as a treatment for prostate cancer before chemotherapy. And nobody seems very happy about it--including NICE itself.

J&J freed from Stryker lawsuit, could face renewed battle with Medinol over stent patents

Like many medical device companies, Johnson & Johnson is waging patent battles on many fronts at once. Recently, two cases in which J&J was the defendant took interesting twists.

Celltrion targets J&J's Remicade as biosimilars loom in the U.S.

South Korea's Celltrion is aiming to be second in line when biosimilars make their U.S. landfall, filing an FDA application to market a knockoff of Johnson & Johnson's blockbuster Remicade.

J&J's diabetes combo wins FDA nod in a fast-crowding space

Johnson & Johnson's canagliflozin was the first to win FDA approval among a new class of diabetes therapies, and now it's the star of the first such combination therapy to pass agency muster, helping the drug stand out in an increasingly cluttered market.

Boston Scientific down on disclosure of subpoena about Bridgepoint acquisition

A Securities and Exchange Commission filing from Aug. 6 disclosed that Boston Scientific received a subpoena from the U.S. Attorney for the District of New Jersey regarding its acquisition of Bridgepoint Medical, leading to a sharp decline in trading.